Miracle Remission: Man Beats Leukemia in Weeks with Clinical Trial

Ryan Goepel initially dismissed his knee pain as a gout flare-up in September 2024. However, persistent pain prompted a doctor's visit, revealing a critical lack of immune system function and an alarming leukemia diagnosis.

Doctors at a local hospital considered hospice care for Goepel, then 49, due to his critical condition. His leukemia was identified as acute myeloid leukemia (AML) with an adverse-risk genetic makeup, complicating standard treatment options.

Fortunately, Goepel qualified for a clinical trial testing two medications typically used for older AML patients. This trial, with openings in September 2024, offered a novel approach for younger individuals with similar genetic profiles.

Within just over two weeks of starting the trial regimen, Goepel achieved remission, a rapid and unexpected outcome. Data from the trial, published in September 2024, showed significant positive responses in many participants.

Following remission, Goepel underwent a bone marrow transplant in November 2024, receiving cells from a matching sister. This procedure was essential for rebuilding his immune system after the intensive treatment.

Now cancer-free for two years as of October 2026, Goepel has married and is resuming his life, reflecting on his near-fatal diagnosis and miraculous recovery. Further research into adverse-risk AML treatments is ongoing.